Primary relevance to vitamin D Vitamin D is a stated subject of this paper.
Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.
Why this paper is included
Supporting source evidence:
The results showed that Vitamin D supplementation significantly reduced the incidence of POAF in CABG patients (RR: 0.55; 95% CI: 0.40 to 0.76; P = 0.0003; I2 = 1%).
Source: Abstract. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Systematic review.
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Meta-analysis reported · Blinding not applicable to this review · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Vitamin D supplementation among postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting: a systematic review and meta-analysis
Source: Article title.
Vitamin D supplementation among postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting: a systematic review and meta-analysis
Source: Article title.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Full studies
Vitamin D supplementation among postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting: a systematic review and meta-analysis
Systematic review · Annals of Medicine and Surgery · 2025
Original publication title
Vitamin D supplementation among postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting: a systematic review and meta-analysis
Copyright © 2025 The Author(s). Published by Wolters Kluwer Health, Inc.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
To determine whether vitamin D supplementation reduces the incidence of postoperative atrial fibrillation (POAF) in patients undergoing coronary artery bypass grafting (CABG).
Source: Aims:Study methods
What methods does the paper describe?
This meta-analysis was performed according to the preferred reporting items for systematic review and meta-analyses PRISMA and AMSTAR guidelines[13,14]. This study was registered in the National Institute for Health Research (NIHR) International Prospective Register of Systematic Reviews (PROSPERO) (Identification No. CRD42024564045)[15].
Literature search
An electronic search was conducted on MEDLINE and Cochrane CENTRAL databases from inception to May 2023, without any language restrictions. Detailed search strategies for the database are provided in the Table S1. http://links.lww.com/MS9/A838. In addition, we manually screened the reference list of retrieved trials, previous meta-analysis, and review articles to identify any relevant studies. The articles retrieved from the systematic search were exported to EndNote Reference Library software where duplicates were screened for and removed. The remaining articles were carefully assessed by two independent reviewers (P.K.L. and F.N.), and only those trials that met the previously defined criteria were selected.
All trials were initially short-listed on the basis of title and abstract, after which the full article was reviewed to affirm relevance. A third investigator (S.A.) was consulted to resolve any discrepancies. Studies were included if they met the following criteria: (i) They were randomized controlled trials; (ii) They involved patients who underwent CABG surgery along with vitamin D deficiency determined before surgery (Vit D level < 21 ng/ml) or insufficiency (Vit D level 21 to 29 ng/ml); (iii) Intervention group patients received vitamin D supplementation along with the standard care in comparison to the control group who had only standard care; (iv) Patients were monitored for postoperative atrial fibrillation (POAF) until discharge.
The definitions for POAF considered for individual studies are mentioned in Supplementary Table 2. http://links.lww.com/MS9/A838. Case-control, cohort, cross-sectional studies, meta-analysis, systematic reviews, follow-up, ongoing studies, and those written in other languages apart from English were excluded.
Outcome extraction and risk of bias assessment
From the finalized trials, the following outcomes were extracted: baseline characteristics displayed in Table 1, incidence of postoperative atrial fibrillation, and length of hospital stay. The revised Cochrane Risk of Bias Tool (RoB 2.0) was used to assess the quality of published trials[16].
Baseline characteristics of the included studies
| First author | CeritL et al | Kara H et al | Talasaz AH et al | Alirezaei T et al | ||||
|---|---|---|---|---|---|---|---|---|
| Vit D group design | RCT | RCT | RCT | RCT | ||||
| Location | CYPRUS | Turkey | Iran | Tehran | ||||
| Publication year | 2018 | 2020 | 2022 | 2024 | ||||
| Intervention | Vit. D | Control | Vit.D | Control | Vit.D | Control | Vit.D | Control |
| No. of participants | 68 | 68 | 58 | 58 | 93 | 103 | 123 | 123 |
| Mean age | 63.8 ± 9.3 | 62.7 ± 8.9 | 64.94 ± 10.52 | 65.21 ± 9.98 | 59.29 (10.10) | 62.22(9.12) | 57.44 ± 6.46 | 58.84 ± 5.69 |
| Male Gender | 37 | 36 | 16 | 13 | 70 | 74 | 102 | 90 |
| Hospital stay (days) | 8.1 ± 2.3 | 7.9 ± 2.1 | 7.14 ± 1.97 | 7.81 ± 2.25 | 7.4 | 9.58 | 19.70 ± 7.43 | 19.27 ± 6.64 |
| BMI | Not reported | Not reported | 26.74 ± 3.96 | 26.62 ± 2.71 | 28.04 | 27.63 | 26.36 ± 2.83 | 26.96 ± 2.30 |
| Diabetes | 25 | 24 | 17 | 22 | 43 | 60 | 58 | 55 |
| Hypertension | 42 | 43 | 36 | 34 | 47 | 58 | 63 | 64 |
| Smoking history | 16 | 18 | Not reported | Not reported | 25 | 29 | 42 | 37 |
| COPD | 19 | 18 | Not reported | Not reported | 3 | 4 | Not reported | Not reported |
| Hyperlipidemia | 16 | 18 | Not reported | Not reported | 49 | 54 | 57 | 60 |
| Statin therapy | 62 | 63 | 27 | 31 | 81 | 91 | 113 | 109 |
| Diuretic therapy | 15 | 14 | Not reported | Not reported | Not reported | Not reported | 60 | 45 |
| Aspirin therapy | 65 | 63 | Not reported | Not reported | Not reported | Not reported | 114 | 112 |
| ACE-I/ARB therapy | 46 | 47 | 23 | 17 | 46 | 61 | 99 | 92 |
| Beta blocker | 58 | 60 | 21 | 26 | 75 | 89 | 109 | 101 |
| Cross-clamping time (min) | 74 (71.0-78.0) | 75 (72-80) | 75.67 ± 23.57 | 71.21 ± 29.52 | Not reported | Not reported | 62.07 ± 13.69 | 59.02 ± 12.15 |
| Pre-op Vit D levels | Not reported | Not reported | Not reported | Not reported | 46.7 | 14.94 | 43.90 ± 11.92 | 67 ± 3.29 |
| Vitamin D levels before supplementation (ng/ml) (Deficiency | 11.4 (6.5-16.3) | 10.9 (5.7-16.1) | 10.77 ± 3.21 | 11.91 ± 3.88 | Not reported | Not reported | 11.73 ± 3.45 | 10.85 ± 3.31 |
| Vitamin D levels before supplementation (ng/ml) (Insufficiency) | 24.6 (20.9-28.3) | 24.9 (21-28.8) | 25.13 ± 3.45 | 27.56 ± 0.70 | 14.43 | 14.94 | Not reported | Not reported |
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockers; BMI, body mass index; COPD, chronic obstructive pulmonary disease; Vit D. vitamin D.
Statistical analysis
RevMan(version 5.3; Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) was used for all statistical analyses. The results from trials were presented as risk ratios (RRs) to compare dichotomous outcomes while weighted mean difference (WMD) was calculated for continuous outcomes with 95% confidence intervals (CIs), and were pooled using a random effect model. Forest plots were created to assess visually the results of pooling. Outcomes of interest were incidence of postoperative atrial fibrillation and length of hospital stay in patients who underwent CABG.
Heterogeneity across studies was evaluated using Higgins I2 and a value less than 50% for I2 was considered acceptable. The funnel plot was visually inspected to assess for publication bias. A P-value of less than 0.05 was considered significant in all cases.
Abstract: Methods and Results
PubMed and Cochrane Central Register of Controlled Trials were systematically searched from inception through May 2023 for randomized controlled trials (RCTs) assessing the effectiveness of Vitamin D in preventing atrial fibrillation among postoperative patients after CABG. The primary outcome extracted was the incidence of atrial fibrillation after Vitamin D in CABG patients. Secondary outcome included the length of hospital stay. Data were pooled using a random-effect model. A total of 4 RCTs, including 694 patients, were included in the final analysis.
The results showed that Vitamin D supplementation significantly reduced the incidence of POAF in CABG patients (RR: 0.55; 95% CI: 0.40 to 0.76; P = 0.0003; I2 = 1%). However, administration of Vitamin D did not lead to significant reduction in the length of hospital stay (WMD: − 0.14; 95% CI: − 0.82 to 0.53; P = 0.68; I2 = 34%).
Source: Methods and Results:Results: Literature search
The initial search yielded a total of 57 articles. The final meta-analysis, after removing duplicates and screening for full text, included four RCTs Cerit, Kara, Talasaz, and Alirezaei[17Not reported20] involving 694 patients. All four studies showed very low risk of bias proving to be high quality studies (Supplementary Figure S1. http://links.lww.com/MS9/A838). The PRISMA flowchart outlines the screening process and exclusion criteria in detail (Fig. 1). PRISMA flowchart outlining the literature search.
Results: Baseline characteristics
The mean age of the patients in the vitamin D group was 61.3 years while the control group was 62.2 years. In the intervention group, 3 days before surgery, patients received a daily dose of 150 000 units of vitamin D orally consisting of 50 000 units per tablet, three times a day, while the control group received placebo tablets (Alirezaaei et al)[20]. In another study, patients received a single oral dose of 50 000 IU of vitamin D (Cerit et al)[17].
In the study by Kara et al, patients with vitamin D deficiency received 300 000 IU of oral vitamin D, while those with insufficiency received 150 000 IU 48 hours before surgery[18]. In the study by Talasaz et al, patients received a single 600 000 IU dose due to the short time to surgery[19]. The mean hospital stay in vitamin D group was 10.58 days while in control group was 11.14 days. Mean Vitamin D levels in before supplementation (deficiency) in the intervention group were 11.3 while in the control group were 11.13.
While the mean Vitamin D levels before supplementation (Insufficiency) in the intervention group were 21.38 while in the control group were 22.46. Baseline characteristics of the included studies are depicted in Table 1.
Baseline characteristics of the included studies
| First author | CeritL et al | Kara H et al | Talasaz AH et al | Alirezaei T et al | ||||
|---|---|---|---|---|---|---|---|---|
| Vit D group design | RCT | RCT | RCT | RCT | ||||
| Location | CYPRUS | Turkey | Iran | Tehran | ||||
| Publication year | 2018 | 2020 | 2022 | 2024 | ||||
| Intervention | Vit. D | Control | Vit.D | Control | Vit.D | Control | Vit.D | Control |
| No. of participants | 68 | 68 | 58 | 58 | 93 | 103 | 123 | 123 |
| Mean age | 63.8 ± 9.3 | 62.7 ± 8.9 | 64.94 ± 10.52 | 65.21 ± 9.98 | 59.29 (10.10) | 62.22(9.12) | 57.44 ± 6.46 | 58.84 ± 5.69 |
| Male Gender | 37 | 36 | 16 | 13 | 70 | 74 | 102 | 90 |
| Hospital stay (days) | 8.1 ± 2.3 | 7.9 ± 2.1 | 7.14 ± 1.97 | 7.81 ± 2.25 | 7.4 | 9.58 | 19.70 ± 7.43 | 19.27 ± 6.64 |
| BMI | Not reported | Not reported | 26.74 ± 3.96 | 26.62 ± 2.71 | 28.04 | 27.63 | 26.36 ± 2.83 | 26.96 ± 2.30 |
| Diabetes | 25 | 24 | 17 | 22 | 43 | 60 | 58 | 55 |
| Hypertension | 42 | 43 | 36 | 34 | 47 | 58 | 63 | 64 |
| Smoking history | 16 | 18 | Not reported | Not reported | 25 | 29 | 42 | 37 |
| COPD | 19 | 18 | Not reported | Not reported | 3 | 4 | Not reported | Not reported |
| Hyperlipidemia | 16 | 18 | Not reported | Not reported | 49 | 54 | 57 | 60 |
| Statin therapy | 62 | 63 | 27 | 31 | 81 | 91 | 113 | 109 |
| Diuretic therapy | 15 | 14 | Not reported | Not reported | Not reported | Not reported | 60 | 45 |
| Aspirin therapy | 65 | 63 | Not reported | Not reported | Not reported | Not reported | 114 | 112 |
| ACE-I/ARB therapy | 46 | 47 | 23 | 17 | 46 | 61 | 99 | 92 |
| Beta blocker | 58 | 60 | 21 | 26 | 75 | 89 | 109 | 101 |
| Cross-clamping time (min) | 74 (71.0-78.0) | 75 (72-80) | 75.67 ± 23.57 | 71.21 ± 29.52 | Not reported | Not reported | 62.07 ± 13.69 | 59.02 ± 12.15 |
| Pre-op Vit D levels | Not reported | Not reported | Not reported | Not reported | 46.7 | 14.94 | 43.90 ± 11.92 | 67 ± 3.29 |
| Vitamin D levels before supplementation (ng/ml) (Deficiency | 11.4 (6.5-16.3) | 10.9 (5.7-16.1) | 10.77 ± 3.21 | 11.91 ± 3.88 | Not reported | Not reported | 11.73 ± 3.45 | 10.85 ± 3.31 |
| Vitamin D levels before supplementation (ng/ml) (Insufficiency) | 24.6 (20.9-28.3) | 24.9 (21-28.8) | 25.13 ± 3.45 | 27.56 ± 0.70 | 14.43 | 14.94 | Not reported | Not reported |
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockers; BMI, body mass index; COPD, chronic obstructive pulmonary disease; Vit D. vitamin D.
Results: Postoperative atrial fibrillation
Four studies compared the effectiveness of Vitamin D supplementation on postoperative atrial fibrillation. Pooling the studies shows that the Vitamin D supplementation significantly reduces the risk POAF (RR: 0.55 [0.40 to 0.76]; P = 0.0003; I2 = 1%) (Fig. 2). Forest plot displaying the incidence of atrial fibrillation after vitamin D in CABG patients.
Results: Length of hospital stay
This forest plot suggests that there is no clear evidence that Vitamin D significantly affects hospital stay duration, (WMD: −0.62[−1.74, 0.50]; P = 0.28; I2 = 82%). High heterogeneity implies that the results varied significantly across the studies as depicted by Fig. 3. Sensitivity analysis showed that the overall effect of Vitamin D on hospital stay duration remains non-significant even after excluding Talasaz AH et al[19]. The combined mean difference is slightly closer to zero, and the heterogeneity is significantly reduced, suggesting that the excluded study contributed to the variability in the original analysis.
However, the results still indicate no clear evidence that vitamin D significantly affects hospital stay duration (WMD: −0.14[−0.82, 0.53]; P = 0.22; I2 = 34%) shown in Fig. 3. Forest plot displaying the length of hospital stay after vitamin D supplementation in CABG patients.
Study limitations
Discussion: What limitations does the paper describe?
Despite the strengths of our meta-analysis including greater sample size than the previous meta-analysis and all studies being randomised control trials, several limitations should be acknowledged. The high heterogeneity observed in the analysis of hospital stay duration suggests that factors such as study design and participant variability may have influenced the outcomes. Additionally, while our study expands the evidence base, the sample size remains limited due to the smaller number of included studies (n = 4), and the generalizability of our findings to other surgical populations or non-CABG patients is uncertain.
Our study focused solely on CABG patients, and we did not assess the effect of vitamin D on other types of surgery. Moreover, there was no predetermined target vitamin D dose to reduce the incidence of atrial fibrillation, and the study was not pre-examined for underlying electrolyte abnormalities, which are one of the precipitating factors for atrial fibrillation. Lastly, our study does not specify the methods used to evaluate the incidence of atrial fibrillation. Clinical outcomes such as myocardial infarction (MI), incidence of survival, cardiac tamponade and cardiac arrest could not be assessed due to limited sample size.
Additionally, while our study incorporated more recent evidence than prior meta-analyses, variability in study designs and outcome definitions may have contributed to increased heterogeneity, particularly regarding length of hospital stay. Future research should address these limitations by conducting well-designed, large-scale RCTs with standardized protocols to provide more definitive conclusions.
Source: Study limitationsResults
Literature search
The initial search yielded a total of 57 articles. The final meta-analysis, after removing duplicates and screening for full text, included four RCTs Cerit, Kara, Talasaz, and Alirezaei[17Not reported20] involving 694 patients. All four studies showed very low risk of bias proving to be high quality studies (Supplementary Figure S1. http://links.lww.com/MS9/A838). The PRISMA flowchart outlines the screening process and exclusion criteria in detail (Fig. 1). PRISMA flowchart outlining the literature search.
Baseline characteristics
The mean age of the patients in the vitamin D group was 61.3 years while the control group was 62.2 years. In the intervention group, 3 days before surgery, patients received a daily dose of 150 000 units of vitamin D orally consisting of 50 000 units per tablet, three times a day, while the control group received placebo tablets (Alirezaaei et al)[20]. In another study, patients received a single oral dose of 50 000 IU of vitamin D (Cerit et al)[17].
In the study by Kara et al, patients with vitamin D deficiency received 300 000 IU of oral vitamin D, while those with insufficiency received 150 000 IU 48 hours before surgery[18]. In the study by Talasaz et al, patients received a single 600 000 IU dose due to the short time to surgery[19]. The mean hospital stay in vitamin D group was 10.58 days while in control group was 11.14 days. Mean Vitamin D levels in before supplementation (deficiency) in the intervention group were 11.3 while in the control group were 11.13.
While the mean Vitamin D levels before supplementation (Insufficiency) in the intervention group were 21.38 while in the control group were 22.46. Baseline characteristics of the included studies are depicted in Table 1.
Postoperative atrial fibrillation
Four studies compared the effectiveness of Vitamin D supplementation on postoperative atrial fibrillation. Pooling the studies shows that the Vitamin D supplementation significantly reduces the risk POAF (RR: 0.55 [0.40 to 0.76]; P = 0.0003; I2 = 1%) (Fig. 2). Forest plot displaying the incidence of atrial fibrillation after vitamin D in CABG patients.
Length of hospital stay
This forest plot suggests that there is no clear evidence that Vitamin D significantly affects hospital stay duration, (WMD: −0.62[−1.74, 0.50]; P = 0.28; I2 = 82%). High heterogeneity implies that the results varied significantly across the studies as depicted by Fig. 3. Sensitivity analysis showed that the overall effect of Vitamin D on hospital stay duration remains non-significant even after excluding Talasaz AH et al[19]. The combined mean difference is slightly closer to zero, and the heterogeneity is significantly reduced, suggesting that the excluded study contributed to the variability in the original analysis.
However, the results still indicate no clear evidence that vitamin D significantly affects hospital stay duration (WMD: −0.14[−0.82, 0.53]; P = 0.22; I2 = 34%) shown in Fig. 3. Forest plot displaying the length of hospital stay after vitamin D supplementation in CABG patients.
Baseline characteristics of the included studies
| First author | CeritL et al | Kara H et al | Talasaz AH et al | Alirezaei T et al | ||||
|---|---|---|---|---|---|---|---|---|
| Vit D group design | RCT | RCT | RCT | RCT | ||||
| Location | CYPRUS | Turkey | Iran | Tehran | ||||
| Publication year | 2018 | 2020 | 2022 | 2024 | ||||
| Intervention | Vit. D | Control | Vit.D | Control | Vit.D | Control | Vit.D | Control |
| No. of participants | 68 | 68 | 58 | 58 | 93 | 103 | 123 | 123 |
| Mean age | 63.8 ± 9.3 | 62.7 ± 8.9 | 64.94 ± 10.52 | 65.21 ± 9.98 | 59.29 (10.10) | 62.22(9.12) | 57.44 ± 6.46 | 58.84 ± 5.69 |
| Male Gender | 37 | 36 | 16 | 13 | 70 | 74 | 102 | 90 |
| Hospital stay (days) | 8.1 ± 2.3 | 7.9 ± 2.1 | 7.14 ± 1.97 | 7.81 ± 2.25 | 7.4 | 9.58 | 19.70 ± 7.43 | 19.27 ± 6.64 |
| BMI | Not reported | Not reported | 26.74 ± 3.96 | 26.62 ± 2.71 | 28.04 | 27.63 | 26.36 ± 2.83 | 26.96 ± 2.30 |
| Diabetes | 25 | 24 | 17 | 22 | 43 | 60 | 58 | 55 |
| Hypertension | 42 | 43 | 36 | 34 | 47 | 58 | 63 | 64 |
| Smoking history | 16 | 18 | Not reported | Not reported | 25 | 29 | 42 | 37 |
| COPD | 19 | 18 | Not reported | Not reported | 3 | 4 | Not reported | Not reported |
| Hyperlipidemia | 16 | 18 | Not reported | Not reported | 49 | 54 | 57 | 60 |
| Statin therapy | 62 | 63 | 27 | 31 | 81 | 91 | 113 | 109 |
| Diuretic therapy | 15 | 14 | Not reported | Not reported | Not reported | Not reported | 60 | 45 |
| Aspirin therapy | 65 | 63 | Not reported | Not reported | Not reported | Not reported | 114 | 112 |
| ACE-I/ARB therapy | 46 | 47 | 23 | 17 | 46 | 61 | 99 | 92 |
| Beta blocker | 58 | 60 | 21 | 26 | 75 | 89 | 109 | 101 |
| Cross-clamping time (min) | 74 (71.0-78.0) | 75 (72-80) | 75.67 ± 23.57 | 71.21 ± 29.52 | Not reported | Not reported | 62.07 ± 13.69 | 59.02 ± 12.15 |
| Pre-op Vit D levels | Not reported | Not reported | Not reported | Not reported | 46.7 | 14.94 | 43.90 ± 11.92 | 67 ± 3.29 |
| Vitamin D levels before supplementation (ng/ml) (Deficiency | 11.4 (6.5-16.3) | 10.9 (5.7-16.1) | 10.77 ± 3.21 | 11.91 ± 3.88 | Not reported | Not reported | 11.73 ± 3.45 | 10.85 ± 3.31 |
| Vitamin D levels before supplementation (ng/ml) (Insufficiency) | 24.6 (20.9-28.3) | 24.9 (21-28.8) | 25.13 ± 3.45 | 27.56 ± 0.70 | 14.43 | 14.94 | Not reported | Not reported |
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockers; BMI, body mass index; COPD, chronic obstructive pulmonary disease; Vit D. vitamin D.
Conclusion
Our updated pooled analysis concludes that preoperative vitamin D supplementation reduces the incidence of POAF in patients who underwent CABG. POAF occurs in approximately a quarter of CABG patients and leads to significant adverse outcomes and increased healthcare costs. Therefore, implementing effective preventive strategies could have substantial clinical and economic benefits, including integrating vitamin D in the preoperative regimen. Our analysis also shows that vitamin D supplementation does not significantly reduce the length of hospital stay. Therefore, its benefits could be specific and limited to arrhythmia prevention.
Future studies, particularly large-scale randomized controlled trials with diverse patient populations, exploring a broader range of cardiovascular and non-cardiovascular outcomes are mandated to better understand the full impact of vitamin D supplementation in CABG patients and to refine its role in clinical practice.”
Source: ConclusionAuthors’ abstract
Aims:
To determine whether vitamin D supplementation reduces the incidence of postoperative atrial fibrillation (POAF) in patients undergoing coronary artery bypass grafting (CABG).
Methods and Results:
PubMed and Cochrane Central Register of Controlled Trials were systematically searched from inception through May 2023 for randomized controlled trials (RCTs) assessing the effectiveness of Vitamin D in preventing atrial fibrillation among postoperative patients after CABG. The primary outcome extracted was the incidence of atrial fibrillation after Vitamin D in CABG patients. Secondary outcome included the length of hospital stay. Data were pooled using a random-effect model. A total of 4 RCTs, including 694 patients, were included in the final analysis.
The results showed that Vitamin D supplementation significantly reduced the incidence of POAF in CABG patients (RR: 0.55; 95% CI: 0.40 to 0.76; P = 0.0003; I2 = 1%). However, administration of Vitamin D did not lead to significant reduction in the length of hospital stay (WMD: − 0.14; 95% CI: − 0.82 to 0.53; P = 0.68; I2 = 34%).
Conclusion:
Our updated pooled analysis concludes that Vitamin D reduces the incidence of POAF in CABG patients. Future large-scale studies should focus on more diverse patient populations and explore a broader range of outcomes to better understand the full impact of Vitamin D supplementation in this context.
Read the full paper
Introduction
Postoperative atrial fibrillation (AF) is a new onset of irregular heart rhythm that typically occurs after surgery, with the highest incidence occurring between the second and fourth days postoperatively. This complication is particularly common following coronary artery bypass grafting (CABG), affecting 20% to 40% of the patients[1]. Individuals who develop postoperative AF are at an eightfold increased risk of progressing to long-term AF and face twice the risk of cardiovascular mortality. Additionally, these patients are at a higher risk of stroke, experience prolonged hospital stays, and contribute to increased health care costs[2Not reported4].
Several factors, both pre-existing and surgery-related, contribute to the onset of postoperative AF. Surgery-related mechanisms include inflammation, oxidative stress, and adrenergic stimulation. Despite preventive strategies such as beta blockers and amiodarone that target these mechanisms, the incidence of postoperative AF remains high[1,5].
HIGHLIGHTS
Early coronary angiography (CAG) in NSTE myocardial infarction improves outcomes, including lower mortality, reduced recurrence, and less frequent revascularization.
It enhances long-term survival and neurological recovery, reflected in better Cerebral Performance Category (CPC) scores at discharge.
Observational studies show more benefits than delayed or no intervention, though randomized trials offer mixed results.
Vitamin D has been recognized for its protective cardiovascular effects, beyond its well-known role in calcium metabolism. It has been shown to lower renin levels, improve glycemic control, and reduce unfavorable cardiac remodeling[6]. Vitamin D also exhibits anti-inflammatory properties by increasing the production of the anti-inflammatory cytokine IL-10 and inhibiting the rise of the pro-inflammatory mediator TNF-alpha[7]. Several studies have suggested a correlation between low vitamin D levels and an increased risk of postoperative AF[8,9].
However, conflicting results from other studies have led to heterogeneity in existing data[10,11]. A previous meta-analysis hinted at a potential association between vitamin D supplementation and a reduction in postoperative AF, but its findings were limited by a small sample size[12]. Hence, in this updated systematic review and meta-analysis, we investigated the impact of oral vitamin D supplementation preoperatively on the development of postoperative AF.
Methods
This meta-analysis was performed according to the preferred reporting items for systematic review and meta-analyses PRISMA and AMSTAR guidelines[13,14]. This study was registered in the National Institute for Health Research (NIHR) International Prospective Register of Systematic Reviews (PROSPERO) (Identification No. CRD42024564045)[15].
Literature search
An electronic search was conducted on MEDLINE and Cochrane CENTRAL databases from inception to May 2023, without any language restrictions. Detailed search strategies for the database are provided in the Table S1. http://links.lww.com/MS9/A838. In addition, we manually screened the reference list of retrieved trials, previous meta-analysis, and review articles to identify any relevant studies. The articles retrieved from the systematic search were exported to EndNote Reference Library software where duplicates were screened for and removed. The remaining articles were carefully assessed by two independent reviewers (P.K.L. and F.N.), and only those trials that met the previously defined criteria were selected.
All trials were initially short-listed on the basis of title and abstract, after which the full article was reviewed to affirm relevance. A third investigator (S.A.) was consulted to resolve any discrepancies. Studies were included if they met the following criteria: (i) They were randomized controlled trials; (ii) They involved patients who underwent CABG surgery along with vitamin D deficiency determined before surgery (Vit D level < 21 ng/ml) or insufficiency (Vit D level 21 to 29 ng/ml); (iii) Intervention group patients received vitamin D supplementation along with the standard care in comparison to the control group who had only standard care; (iv) Patients were monitored for postoperative atrial fibrillation (POAF) until discharge.
The definitions for POAF considered for individual studies are mentioned in Supplementary Table 2. http://links.lww.com/MS9/A838. Case-control, cohort, cross-sectional studies, meta-analysis, systematic reviews, follow-up, ongoing studies, and those written in other languages apart from English were excluded.
Outcome extraction and risk of bias assessment
From the finalized trials, the following outcomes were extracted: baseline characteristics displayed in Table 1, incidence of postoperative atrial fibrillation, and length of hospital stay. The revised Cochrane Risk of Bias Tool (RoB 2.0) was used to assess the quality of published trials[16].
Baseline characteristics of the included studies
| First author | CeritL et al | Kara H et al | Talasaz AH et al | Alirezaei T et al | ||||
|---|---|---|---|---|---|---|---|---|
| Vit D group design | RCT | RCT | RCT | RCT | ||||
| Location | CYPRUS | Turkey | Iran | Tehran | ||||
| Publication year | 2018 | 2020 | 2022 | 2024 | ||||
| Intervention | Vit. D | Control | Vit.D | Control | Vit.D | Control | Vit.D | Control |
| No. of participants | 68 | 68 | 58 | 58 | 93 | 103 | 123 | 123 |
| Mean age | 63.8 ± 9.3 | 62.7 ± 8.9 | 64.94 ± 10.52 | 65.21 ± 9.98 | 59.29 (10.10) | 62.22(9.12) | 57.44 ± 6.46 | 58.84 ± 5.69 |
| Male Gender | 37 | 36 | 16 | 13 | 70 | 74 | 102 | 90 |
| Hospital stay (days) | 8.1 ± 2.3 | 7.9 ± 2.1 | 7.14 ± 1.97 | 7.81 ± 2.25 | 7.4 | 9.58 | 19.70 ± 7.43 | 19.27 ± 6.64 |
| BMI | Not reported | Not reported | 26.74 ± 3.96 | 26.62 ± 2.71 | 28.04 | 27.63 | 26.36 ± 2.83 | 26.96 ± 2.30 |
| Diabetes | 25 | 24 | 17 | 22 | 43 | 60 | 58 | 55 |
| Hypertension | 42 | 43 | 36 | 34 | 47 | 58 | 63 | 64 |
| Smoking history | 16 | 18 | Not reported | Not reported | 25 | 29 | 42 | 37 |
| COPD | 19 | 18 | Not reported | Not reported | 3 | 4 | Not reported | Not reported |
| Hyperlipidemia | 16 | 18 | Not reported | Not reported | 49 | 54 | 57 | 60 |
| Statin therapy | 62 | 63 | 27 | 31 | 81 | 91 | 113 | 109 |
| Diuretic therapy | 15 | 14 | Not reported | Not reported | Not reported | Not reported | 60 | 45 |
| Aspirin therapy | 65 | 63 | Not reported | Not reported | Not reported | Not reported | 114 | 112 |
| ACE-I/ARB therapy | 46 | 47 | 23 | 17 | 46 | 61 | 99 | 92 |
| Beta blocker | 58 | 60 | 21 | 26 | 75 | 89 | 109 | 101 |
| Cross-clamping time (min) | 74 (71.0-78.0) | 75 (72-80) | 75.67 ± 23.57 | 71.21 ± 29.52 | Not reported | Not reported | 62.07 ± 13.69 | 59.02 ± 12.15 |
| Pre-op Vit D levels | Not reported | Not reported | Not reported | Not reported | 46.7 | 14.94 | 43.90 ± 11.92 | 67 ± 3.29 |
| Vitamin D levels before supplementation (ng/ml) (Deficiency | 11.4 (6.5-16.3) | 10.9 (5.7-16.1) | 10.77 ± 3.21 | 11.91 ± 3.88 | Not reported | Not reported | 11.73 ± 3.45 | 10.85 ± 3.31 |
| Vitamin D levels before supplementation (ng/ml) (Insufficiency) | 24.6 (20.9-28.3) | 24.9 (21-28.8) | 25.13 ± 3.45 | 27.56 ± 0.70 | 14.43 | 14.94 | Not reported | Not reported |
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockers; BMI, body mass index; COPD, chronic obstructive pulmonary disease; Vit D. vitamin D.
Statistical analysis
RevMan(version 5.3; Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) was used for all statistical analyses. The results from trials were presented as risk ratios (RRs) to compare dichotomous outcomes while weighted mean difference (WMD) was calculated for continuous outcomes with 95% confidence intervals (CIs), and were pooled using a random effect model. Forest plots were created to assess visually the results of pooling. Outcomes of interest were incidence of postoperative atrial fibrillation and length of hospital stay in patients who underwent CABG.
Heterogeneity across studies was evaluated using Higgins I2 and a value less than 50% for I2 was considered acceptable. The funnel plot was visually inspected to assess for publication bias. A P-value of less than 0.05 was considered significant in all cases.
Results
Literature search
The initial search yielded a total of 57 articles. The final meta-analysis, after removing duplicates and screening for full text, included four RCTs Cerit, Kara, Talasaz, and Alirezaei[17Not reported20] involving 694 patients. All four studies showed very low risk of bias proving to be high quality studies (Supplementary Figure S1. http://links.lww.com/MS9/A838). The PRISMA flowchart outlines the screening process and exclusion criteria in detail (Fig. 1). PRISMA flowchart outlining the literature search.
Baseline characteristics
The mean age of the patients in the vitamin D group was 61.3 years while the control group was 62.2 years. In the intervention group, 3 days before surgery, patients received a daily dose of 150 000 units of vitamin D orally consisting of 50 000 units per tablet, three times a day, while the control group received placebo tablets (Alirezaaei et al)[20]. In another study, patients received a single oral dose of 50 000 IU of vitamin D (Cerit et al)[17].
In the study by Kara et al, patients with vitamin D deficiency received 300 000 IU of oral vitamin D, while those with insufficiency received 150 000 IU 48 hours before surgery[18]. In the study by Talasaz et al, patients received a single 600 000 IU dose due to the short time to surgery[19]. The mean hospital stay in vitamin D group was 10.58 days while in control group was 11.14 days. Mean Vitamin D levels in before supplementation (deficiency) in the intervention group were 11.3 while in the control group were 11.13.
While the mean Vitamin D levels before supplementation (Insufficiency) in the intervention group were 21.38 while in the control group were 22.46. Baseline characteristics of the included studies are depicted in Table 1.
Postoperative atrial fibrillation
Four studies compared the effectiveness of Vitamin D supplementation on postoperative atrial fibrillation. Pooling the studies shows that the Vitamin D supplementation significantly reduces the risk POAF (RR: 0.55 [0.40 to 0.76]; P = 0.0003; I2 = 1%) (Fig. 2). Forest plot displaying the incidence of atrial fibrillation after vitamin D in CABG patients.
Length of hospital stay
This forest plot suggests that there is no clear evidence that Vitamin D significantly affects hospital stay duration, (WMD: −0.62[−1.74, 0.50]; P = 0.28; I2 = 82%). High heterogeneity implies that the results varied significantly across the studies as depicted by Fig. 3. Sensitivity analysis showed that the overall effect of Vitamin D on hospital stay duration remains non-significant even after excluding Talasaz AH et al[19]. The combined mean difference is slightly closer to zero, and the heterogeneity is significantly reduced, suggesting that the excluded study contributed to the variability in the original analysis.
However, the results still indicate no clear evidence that vitamin D significantly affects hospital stay duration (WMD: −0.14[−0.82, 0.53]; P = 0.22; I2 = 34%) shown in Fig. 3. Forest plot displaying the length of hospital stay after vitamin D supplementation in CABG patients.
Discussion
This meta-analysis of 694 patients undergoing CABG; with either vitamin D deficiency or insufficiency shows that vitamin D supplementation preoperatively was associated with a lower incidence of postoperative atrial fibrillation. No effect on length of hospital stay was noted
Our meta-analysis confirms that preoperative vitamin D supplementation is associated with a significant reduction in POAF incidence. This finding is consistent with earlier studies but is bolstered by the inclusion of additional participants, enhancing the robustness of the evidence. The presence of vitamin D receptors in cardiac muscle cells and its anti-inflammatory effects, such as reducing cardiac fibrosis and inflammation, likely contribute to this protective effect[21,22]. This result underscores the potential of vitamin D as a preventive measure in high-risk surgical populations, particularly those undergoing CABG.
Our findings also align with studies reporting that correcting vitamin D deficiency through supplementation significantly reduces atrial electromechanical delay (AEMD), a known risk factor for AF[23]. The reduction in AEMD may contribute to the decreased risk of developing AF, reinforcing the role of vitamin D in maintaining normal cardiac rhythm[23]. This aspect of vitamin D’s action is particularly important, as it suggests a direct electrophysiological mechanism through which vitamin D exerts its protective effects against POAF.
Vitamin D deficiency plays a significant role in modifying the heart’s electrophysiology, such as shortening the action potentials and the refractory period of the atrial myocardium through both direct and indirect actions. This results in elevated intracellular calcium levels within cardiac myocytes, which leads to an imbalance in electrolytes. This imbalance alters cardiac electrophysiology and contractility[24,25]. The study by Hanafy et al demonstrated an increase in action potential duration and contractility in the atrium following vitamin D administration, suggesting that it may be an effective therapy for preventing POAF[26].
Contrary to the reduction in POAF, our analysis did not find clear evidence that vitamin D supplementation significantly affects hospital stay duration. The high heterogeneity observed in this outcome suggests variability across studies, which may stem from differences in study design, participant characteristics, or intervention protocols. A sensitivity analysis excluding the study by Talasaz AH et al reduced heterogeneity but did not alter the non-significant finding[19]. This highlights the complexity of assessing hospital stay duration as an outcome and suggests that while vitamin D may reduce POAF, its effect on hospitalization length is less clear and warrants further investigation.
Previous meta-analyses, including those by Hameed, Rahimi, and Liu, have explored the association between vitamin D and POAF, but the findings have been inconsistent due to variability in study designs, participant characteristics, and the timing of vitamin D measurements. Hameed’s analysis included three randomized controlled trials (RCTs) with 448 participants, suggesting a decrease in POAF and hospital stay with preoperative vitamin D supplementation. However, the small sample size limited the generalizability of these findings[13]. A previous meta-analysis by Hameed et al (2023) included three RCTs (n = 448) and reported a significant reduction in POAF incidence with vitamin D supplementation, along with a non-significant trend toward reduced hospital stay.
Our study expands on these findings by incorporating an additional RCT, increasing the total sample size to 694. While our results similarly indicate a significant reduction in POAF, the reduction in length of hospital stay remained non-significant. Notably, our analysis exhibited greater heterogeneity in the LOS outcome, which may be attributed to differences in patient populations, vitamin D dosing regimens, timing of administration, and perioperative care protocols across the included studies. This highlights the need for further standardized research in this area.
These contributions improve the understanding of vitamin D’s role in cardiac surgery and support its potential use in perioperative management strategies. Rahimi’s meta-analysis of five observational studies highlighted age as a significant confounding factor, emphasizing the need for careful matching in studies[27]. Liu’s larger meta-analysis with 74 885 participants identified Vitamin D deficiency as a moderate predictor of AF, yet heterogeneity remained a significant concern[28]. Our updated meta-analysis builds on this existing literature by incorporating a new RCT by Alirazei, increasing the total number of participants to 694[20].
This expansion strengthens the evidence base and addresses the gaps left by prior studies, particularly in the context of preoperative Vitamin D supplementation in CABG patients.
The findings of our meta-analysis suggest that preoperative Vitamin D supplementation could be a valuable strategy in reducing the incidence of POAF in patients undergoing CABG. This has significant implications for clinical practice, as it offers a relatively simple and low-cost intervention to mitigate a common and serious postoperative complication. However, our results also highlight the need for large-scale RCTs to confirm these benefits, determine the optimal dosage, and evaluate the long-term effects of vitamin D supplementation on POAF recurrence, cardiovascular morbidity, and mortality.
Study limitations
Despite the strengths of our meta-analysis including greater sample size than the previous meta-analysis and all studies being randomised control trials, several limitations should be acknowledged. The high heterogeneity observed in the analysis of hospital stay duration suggests that factors such as study design and participant variability may have influenced the outcomes. Additionally, while our study expands the evidence base, the sample size remains limited due to the smaller number of included studies (n = 4), and the generalizability of our findings to other surgical populations or non-CABG patients is uncertain.
Our study focused solely on CABG patients, and we did not assess the effect of vitamin D on other types of surgery. Moreover, there was no predetermined target vitamin D dose to reduce the incidence of atrial fibrillation, and the study was not pre-examined for underlying electrolyte abnormalities, which are one of the precipitating factors for atrial fibrillation. Lastly, our study does not specify the methods used to evaluate the incidence of atrial fibrillation. Clinical outcomes such as myocardial infarction (MI), incidence of survival, cardiac tamponade and cardiac arrest could not be assessed due to limited sample size.
Additionally, while our study incorporated more recent evidence than prior meta-analyses, variability in study designs and outcome definitions may have contributed to increased heterogeneity, particularly regarding length of hospital stay. Future research should address these limitations by conducting well-designed, large-scale RCTs with standardized protocols to provide more definitive conclusions.
Conclusion
Our updated pooled analysis concludes that preoperative vitamin D supplementation reduces the incidence of POAF in patients who underwent CABG. POAF occurs in approximately a quarter of CABG patients and leads to significant adverse outcomes and increased healthcare costs. Therefore, implementing effective preventive strategies could have substantial clinical and economic benefits, including integrating vitamin D in the preoperative regimen. Our analysis also shows that vitamin D supplementation does not significantly reduce the length of hospital stay. Therefore, its benefits could be specific and limited to arrhythmia prevention.
Future studies, particularly large-scale randomized controlled trials with diverse patient populations, exploring a broader range of cardiovascular and non-cardiovascular outcomes are mandated to better understand the full impact of vitamin D supplementation in CABG patients and to refine its role in clinical practice.”
Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.
Supplemental Digital Content is available for this article. Direct URL citations are provided in the HTML and PDF versions of this article on the journal’s website, www.lww.com/annals-of-medicine-and-surgery.
Ethical approval
Not required because data was publicly available.
Consent
Consent for this article was not required because data were publicly available.
Sources of funding
None.
Author contributions
T.A., M.A.M., G.K., A.K., and V.K. drafted the manuscript. F.N.U.S. and N.K.L. conducted the literature review. T.H., S.D., M.T., V.A., and U.E. contributed to the formal analysis. S.J. critically reviewed and revised the manuscript.
Conflicts of interest disclosure
None.
Research registration unique identifying number (UIN)
NA National; Institute for Health Research (NIHR) International prospective register of systematic reviews (PROSPERO) (Identification No. CRD42024582058).
Guarantor
Sayed Jawad.
Provenance and peer review
Not commissioned, externally peer-reviewed.
Data availability statement
Not applicable.
References
Publication and source details
Original title: Vitamin D supplementation among postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting: a systematic review and meta-analysis
Taimoor Ashraf; Muhammad Abdul Moiz; Ganesh Kumar; Akshay Kumar; Vishal Kumar; Vivek Anand; Fnu Sunita; Naresh Kumar Ladhwani; Tooba Hussain; Shah Dev; Muskan Turesh; Sadia Habib Bhutto; Umer Ejaz; Sayed Jawad
Annals of Medicine and Surgery · 2025
* Corresponding author. Address: Department of Medicine, Kabul University of Medical Sciences, Ataturk Karte Sakhi Road, Kabul 1003, Afghanistan. Tel.:+93 (20) 250 0327. E-mail: sayedjawad12345@outlook.com (S. Jawad).Copyright © 2025 The Author(s). Published by Wolters Kluwer Health, Inc.2025https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T01:28:42.949818+00:00
DOI: 10.1097/ms9.0000000000003426 · PMC12369816